RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Fumagalli, Debora; Venet, David; Ignatiadis, Michail; Azim, Hatem A; Maetens, Marion; Rothé, Françoise; Salgado, Roberto; Bradbury, Ian; Pusztai, Lajos; Harbeck, Nadia; Gomez, Henry; Chang, Tsai-Wang; Coccia-Portugal, Maria Antonia; Di Cosimo, Serena; de Azambuja, Evandro; de la Peña, Lorena; Nuciforo, Paolo; Brase, Jan C; Huober, Jens; Baselga, José; Piccart, Martine; Loi, Sherene; Sotiriou, Christos

Fumagalli, Debora; Venet, David; Ignatiadis, Michail; Azim, Hatem A; Maetens, Marion; Rothé, Françoise; Salgado, Roberto; Bradbury, Ian; Pusztai, Lajos; Harbeck, Nadia; Gomez, Henry; Chang, Tsai-Wang; Coccia-Portugal, Maria Antonia; Di Cosimo, Serena; de Azambuja, Evandro; de la Peña, Lorena; Nuciforo, Paolo; Brase, Jan C; Huober, Jens; Baselga, José; Piccart, Martine; Loi, Sherene; Sotiriou, Christos.

Afiliação

Fumagalli D; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Venet D; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Ignatiadis M; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Azim HA; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Maetens M; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Rothé F; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Salgado R; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Bradbury I; Frontier Science Scotland, Kincraig, Inverness-shire, Scotland.
Pusztai L; Breast Medical Oncology Section, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Harbeck N; Breast Center, Department of Obstetrics and Gynecology, University of Munich, Munich, Germany.
Gomez H; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Chang TW; Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan.
Coccia-Portugal MA; Clinical Trial Department, Eastleigh Breast Care Centre, Pretoria, South Africa.
Di Cosimo S; Department of Oncology, Istituto Nazionale Tumori, Milan, Italy.
de Azambuja E; Breast European Adjuvant Study Team, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
de la Peña L; SOLTI-Breast Cancer Research Group, Barcelona, Spain.
Nuciforo P; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Brase JC; Novartis Pharmaceutical, Basel, Switzerland.
Huober J; Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany.
Baselga J; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Piccart M; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Loi S; Division of Cancer Medicine and Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia.
Sotiriou C; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium15Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

JAMA Oncol ; 3(2): 227-234, 2017 Feb 01.

Article em En | MEDLINE | ID: mdl-27684533

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JAMA Oncol Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google